Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN 3 COMBINATION PACK versus KETOCONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN 3 COMBINATION PACK versus KETOCONAZOLE.
GYNE-LOTRIMIN 3 COMBINATION PACK vs KETOCONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability. The combination pack includes an insert for vaginal use and a topical cream for external use.
Inhibits fungal cytochrome P450 14α-demethylase, impairing ergosterol synthesis and disrupting fungal cell membrane integrity.
Vaginal suppository: 200 mg at bedtime for 3 nights; topical cream (2%): apply intravaginally once daily for 3 nights.
200-400 mg orally once daily for superficial fungal infections; 400 mg orally once daily for systemic mycoses. Duration varies by indication.
None Documented
None Documented
Clinical Note
moderateKetoconazole + Tranilast
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tranilast."
Clinical Note
moderateKetoconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tolfenamic acid."
Clinical Note
moderateKetoconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Nimesulide."
Clinical Note
moderateTerminal half-life of absorbed clotrimazole is approximately 3.5-6 hours; clinically, topical application maintains local concentrations without reliance on systemic half-life.
Biphasic elimination: initial half-life 2-4 hours, terminal half-life 6-10 hours in adults. In severe hepatic impairment, half-life may be prolonged up to 12-20 hours.
Clotrimazole: ~0.03% of topical dose excreted renally as metabolites; majority eliminated in feces via biliary excretion. Vaginal administration: minimal systemic absorption (<3%), with absorbed drug primarily metabolized hepatically and excreted in bile/feces.
Primarily metabolized in the liver; about 70% of the dose is excreted in feces via bile as metabolites, approximately 20-30% in urine (mostly as inactive metabolites), and less than 5% unchanged.
Category C
Category C
Azole Antifungal
Azole Antifungal
Ketoconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Risedronic acid."